Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain.
D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000037:antagonists & inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D001921:Brain / Q000201:enzymology*; D002118:Calcium / Q000494:pharmacology; D002417:Cattle; D002746:Chlorpromazine / Q000494:pharmacology; D006152:Cyclic GMP; D004533:Egtazic Acid / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D066298:In Vitro Techniques; D010726:Phosphodiesterase Inhibitors; D011619:Psychotropic Drugs / Q000494:pharmacology*; D051381:Rats; D014268:Trifluoperazine / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D011619:Psychotropic Drugs; D014268:Trifluoperazine; D004533:Egtazic Acid; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D006152:Cyclic GMP; D002118:Calcium; D002746:Chlorpromazine